Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology 2016;123:697–708.
Siatkowski RM, Cotter S, Miller JM, Scher CA, Crockett RS, Novack GD, et al. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol. 2004;122:1667–74.
Fricke T, Hurairah H, Huang Y, Ho SM. Pharmacological interventions in myopia management. Community Eye Health. 2019;32:21–2.
Mezer E, Zloto O, Farzavandi SK, Gomez-de-Liano RM, Sprunger DT, Wygnanski-Jaffe T. Current trends to decrease myopia progression survey: an IPOSC global study. J Am Assoc Pediatr Ophthalmol Strabismus JAAPOS. 2018;22:e73.
McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993;34:205–15.
Upadhyay A, Beuerman RW. Biological Mechanisms of Atropine Control of Myopia. Eye Contact Lens. 2020;46:129–35.
Phillips JR, Khalaj M, McBrien NA. Induced myopia associated with increased scleral creep in chick and tree shrew eyes. Invest Ophthalmol Vis Sci. 2000;41:2028–34.
Metlapally R, Wildsoet CF. Scleral Mechanisms Underlying Ocular Growth and Myopia. Prog Mol Biol Transl Sci. 2015;134:241–8.
Curtin BJ, Iwamoto T, Renaldo DP. Normal and staphylomatous sclera of high myopia. An electron microscopic study. Arch Ophthalmol Chic Ill 1960. 1979;97:912–5.
Avetisov ES, Savitskaya NF, Vinetskaya MI, Iomdina EN. A study of biochemical and biomechanical qualities of normal and myopic eye sclera in humans of different age groups. Metab Pediatr Syst Ophthalmol. 1983;7:183–8.
Barathi VA, Weon SR, Beuerman RW. Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis. 2009;15:1277–93.
Lind GJ, Chew SJ, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci. 1998;39:2217–31.
Carr BJ, Mihara K, Ramachandran R, Saifeddine M, Nathanson NM, Stell WK, et al. Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro. Invest Ophthalmol Vis Sci. 2018;59:2778–91.
Barathi VA, Chaurasia SS, Poidinger M, Koh SK, Tian D, Ho C, et al. Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics. J Proteome Res. 2014;13:4647–58.
Chiang STH, Chen TL, Phillips JR. Effect of Optical Defocus on Choroidal Thickness in Healthy Adults With Presbyopia. Invest Ophthalmol Vis Sci. 2018;59:5188–93.
Marzani D, Wallman J. Growth of the two layers of the chick sclera is modulated reciprocally by visual conditions. Invest Ophthalmol Vis Sci. 1997;38:1726–39.
Aldakhil S The Effect of Optical Defocus on the Choroidal Thickness: A Review. Open Ophthalmol J [Internet]. 2021 Dec 28 [cited 2022 Jul 29];15. Available from: https://openophthalmologyjournal.com/VOLUME/15/PAGE/283/FULLTEXT/
Chiang STH, Phillips JR. Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus. J Ophthalmol. 2018;2018:8528315.
Chiang STH, Turnbull PRK, Phillips JR. Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia. Sci Rep. 2020;10:18310.
Tan J, Deng ZH, Liu SZ, Wang JT, Huang C. TGF-beta2 in human retinal pigment epithelial cells: expression and secretion regulated by cholinergic signals in vitro. Curr Eye Res. 2010;35:37–44.
Seko Y, Tanaka Y, Tokoro T. Influence of bFGF as a potent growth stimulator and TGF-beta as a growth regulator on scleral chondrocytes and scleral fibroblasts in vitro. Ophthalmic Res. 1995;27:144–52.
Yam JC, Jiang Y, Lee J, Li S, Zhang Y, Sun W, et al. The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) Study. Am J Ophthalmol. 2021;237:130–8.
Tian J, Wei S, Li S, An W, Bai W, Liang X, et al. The effect of atropine 0.01% eyedrops on relative peripheral refraction in myopic children. Eye Lond Engl. 2023;37:356–61.
Donders FC. On the anomalies of accommodation and refraction of the eye. New Sydenham Soc. 1864;34:443–5.
GALVIS V, TELLO A, PARRA MM, MERAYO-LLOVES J, LARREA J, JULIAN RODRIGUEZ C, et al. Topical Atropine in the Control of Myopia. Med Hypothesis Discov Innov Ophthalmol. 2016;5:78–88.
Pollock WBI. The Reduction of Myopia in Children of School Age *Presented to the Association of School Medical Officers of Scotland on 18th March, 1915. Glas Med J. 1916;86:214–9.
Gostin S. Prophylatic management of progressive myopia. South Med J. 1962;55:916–20.
Bedrossian RH. The effect of atropine on myopia. Ophthalmology 1979;86:713–9.
Kennedy RH. Progression of myopia. Trans Am Ophthalmol Soc. 1995;93:755–800.
Kelly TS, Chatfield C, Tustin G. Clinical assessment of the arrest of myopia. Br J Ophthalmol. 1975;59:529–38.
Gruber E. The treatment of myopia with atropine: A clinical study. Excerpta Med Int Congr Ser. 1979;1:1212–6.
Brodstein RS, Brodstein DE, Olson RJ, Hunt SC, Williams RR. The Treatment of Myopia with Atropine and Bifocals: A Long-term Prospective Study. Ophthalmology 1984;91:1373–8.
Gimbel HV. The control of myopia with atropine. Can J Ophthalmol J Can Ophtalmol. 1973;8:527–32.
Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989;21:180–2.
Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharm Ther. 1999;15:85–90.
Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology 2020;127:910–9.
Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology 2019;126:113–24.
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012;119:347–54.
Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2. Ophthalmology 2016;123:391–9.
Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285–91.
Tong L, Huang XL, Koh ALT, Zhang XE, Tan DTH, Chua WH. Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of Atropine. Ophthalmology 2009;116:572–9.
Bullimore MA, Berntsen DA. Low-Dose Atropine for Myopia Control: Considering All the Data. JAMA Ophthalmol. 2018;136:303.
Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology 2022;129:308–21.
Bullimore MA, Brennan NA. Efficacy in Myopia Control: The Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology 2023;130:771–2.
Loh KL, Lu QS, Tan D, Chia A. Risk Factors for Progressive Myopia in the Atropine Therapy for Myopia Study. Am J Ophthalmol. 2015;159:945–9.
Li FF, Zhang Y, Zhang X, Kei Yip BH, Tang SM, Kam KW, et al. Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology 2021;07:07.
Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of Age at Myopia Onset With Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JAMA Ophthalmol. 2020;138:1129–34.
Cooper J, Eisenberg N, Schulman E, Wang FM. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci Publ Am Acad Optom. 2013;90:1467–72.
Lee CY, Sun CC, Lin YF, Lin KK. Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study. BMC Ophthalmol. 2016;16:114.
Chia A, Li W, Tan D, Luu CD. Full-field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study. Doc Ophthalmol Adv Ophthalmol. 2013;126:177–86.
Luu CD, Lau AMI, Koh AHC, Tan D. Multifocal electroretinogram in children on atropine treatment for myopia. Br J Ophthalmol. 2005;89:151–3.
Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for treatment of childhood myopia in India (I-ATOM): multicentric randomized trial. Ophthalmology 2021;02:02.
Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;14:14.
Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020;104:1535–41.
Cui C, Li X, Lyu Y, Wei L, Zhao B, Yu S, et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. 2021;11:22267.
Lee SSY, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001–12.
Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023;e232097. https://doi.org/10.1001/jamaophthalmol.2023.2097. Epub ahead of print.
R Handbook: What are Least Square Means? [Internet]. [cited 2023 Jun 17]. Available from: https://rcompanion.org/handbook/G_05.html
Bausch & Lomb Incorporated. A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study) [Internet]. clinicaltrials.gov; 2021 Dec [cited 2022 Apr 24]. Report No.: NCT03942419. Available from: https://clinicaltrials.gov/ct2/show/NCT03942419
Vyluma, Inc. A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia [Internet]. clinicaltrials.gov; 2022 Feb [cited 2022 Apr 24]. Report No.: NCT03350620. Available from: https://clinicaltrials.gov/ct2/show/NCT03350620
Sydnexis, Inc. A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children [Internet]. clinicaltrials.gov; 2022 Jan [cited 2022 Apr 24]. Report No.: NCT03918915. Available from: https://clinicaltrials.gov/ct2/show/NCT03918915
Clinical Trials register – Search for Atropine [Internet]. [cited 2022 Feb 15]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=Atropine
Gan J, Li SM, Wu S, Cao K, Ma D, He X, et al. Varying Dose of Atropine in Slowing Myopia Progression in Children Over Different Follow-Up Periods by Meta-Analysis. Front Med. 2022;8:756398.
Zhao C, Cai C, Ding Q, Dai H. Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis. BMC Ophthalmol. 2020;20:478.
Bullimore MA, Logan NS. Optical Interventions for Myopia Control. Eye Lond Engl. 2023; https://doi.org.uk/10.1038/s41433-023-02723-5
Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol. 2018;62:544–53.
Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10:11.
Gao C, Wan S, Zhang Y, Han J. The Efficacy of Atropine Combined With Orthokeratology in Slowing Axial Elongation of Myopia Children: A Meta-Analysis. Eye Contact Lens. 2021;47:98–103.
Yang N, Bai J, Liu L. Low concentration atropine combined with orthokeratology in the treatment of axial elongation in children with myopia: A meta-analysis. Eur J Ophthalmol. 2022;32:221–8.
Zhou H, Zhao G, Li Y. Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia. Clin Exp Optom. 2022;105:520–6.
Tan Q, Ng ALK, Choy BNK, Cheng GPM, Woo VCP, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40:557–66.
Bullimore MA, Brennan NA. Efficacy in Myopia Control: Does Race Matter? Optom Vis Sci Publ Am Acad Optom. 2023;100:5–8.
Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta Ophthalmol (Copenh). 2019;97:e1136–40.
Pérez-Flores I, Macías-Murelaga B, Barrio-Barrio J. A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2021;11:21748.
Joachimsen L, Böhringer D, Gross NJ, Reich M, Stifter J, Reinhard T, et al. A Pilot Study on the Efficacy and Safety of 0.01% Atropine in German Schoolchildren with Progressive Myopia. Ophthalmol Ther. 2019;8:427–33.
Azuara-Blanco A, Logan N, Strang N, Saunders K, Allen PM, Weir R, et al. Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol. Br J Ophthalmol. 2020;104:950–5.
McCrann S, Flitcroft I, Strang NC, Saunders KJ, Logan NS, Lee SS, et al. Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Res. 2019;2:15.
Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci Publ Am Acad Optom. 2019;96:463–5.
COMET Group. Myopia Stabilization and Associated Factors Among Participants in the Correction of Myopia Evaluation Trial (COMET). Invest Ophthalmol Vis Sci. 2013;54:7871–84.
Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923.
Klaver C CW, Polling JR, Group EMR. Myopia management in the Netherlands. Ophthalmic Physiol Opt. 2020;40:230–40.
Parssinen O, Kauppinen M, Viljanen A. The progression of myopia from its onset at age 8-12 to adulthood and the influence of heredity and external factors on myopic progression. A 23-year follow-up study. Acta Ophthalmol (Copenh). 2014;92:730–9.
Tsai HR, Chen TL, Wang JH, Huang HK, Chiu CJ. Is 0.01% Atropine an Effective and Safe Treatment for Myopic Children? A Systemic Review and Meta-Analysis. J Clin Med. 2021;10:3766.
Wei-Lin AC. The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3) [Internet]. clinicaltrials.gov; 2017 Oct [cited 2022 Feb 16]. Report No.: NCT03140358. Available from: https://clinicaltrials.gov/ct2/show/NCT03140358
Jethani J. Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes. Indian J Ophthalmol. 2022;70:238–40.
Fang PC, Chung MY, Yu HJ, Wu PC. Prevention of myopia onset with 0.025% atropine in premyopic children. J Ocul Pharm Ther J Assoc Ocul Pharm Ther. 2010;26:341–5.
Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, Wong ES, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA 2023;329:472–81.
Richdale K, Tomiyama ES, Novack GD, Bullimore MA. Compounding of Low-Concentration Atropine for Myopia Control. Eye Contact Lens. 2022;48:489–92.
Berton B, Chennell P, Yessaad M, Bouattour Y, Jouannet M, Wasiak M. et al. Stability of Ophthalmic Atropine Solutions for Child Myopia Control. Pharmaceutics. 2020;12:781